Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)

A Multicenter, Open Study To Evaluate The Efficacy Of Ezetimibe 10 Mg Added On Statin Therapy, In Reducing LDL Cholesterol To Target Levels In Patients After Acute Coronary Syndrome

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00652717

Enrollment

280

Registered

2008-04-04

Start date

2005-02-01

Completion date

2005-08-04

Last updated

2024-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disorder

Brief summary

Collecting local data, safety and experience trial.

Interventions

DRUGEzetimibe

Ezetimibe 10 mg daily for 42 days.

DRUGsimvastatin

simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients; Post Acute Coronary Syndrome

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
LDL levels	42 Days

Secondary

Measure	Time frame
Safety measures	42 days
Total cholesterol levels.	42 Days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026